.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Dow
Queensland Health
Moodys
Fuji
Cipla
McKesson
Cantor Fitzgerald
Boehringer Ingelheim
Julphar

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,177,557

« Back to Dashboard

Details for Patent: 6,177,557

Title: High affinity ligands of basic fibroblast growth factor and thrombin
Abstract:The present invention utilizes the SELEX (Systematic Evolution of Ligands for EXponential Enrichment) method for identifying and preparing nucleic acid ligands to basic fibroblast growth factor (bFGF) and thrombin. Included in the invention are nucleic acid ligands to bFGF which are inhibitors of bFGF and 2'-amino-modified RNA ligands to bFGF. Further included in the present invention are modified nucleotide sequences to thrombin based on the sequences of the RNA ligands identified. The modified RNA ligands to bFGF and thrombin exhibit increased in vivo stability.
Inventor(s): Janjic; Nebojsa (Boulder, CO), Gold; Larry (Boulder, CO), Tasset; Diane (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Aug 05, 1996
Application Number:08/687,421
Claims:1. A purified and isolated non-naturally occurring DNA ligand to bFGF wherein the nucleic acid sequence of said ligand is selected from the group consisting of SEQ ID NOS: 330-444.

2. A purified and isolated non-naturally occurring nucleic acid ligand to bFGF wherein the nucleic acid sequence of said ligand is substantially homologous to and has substantially the same ability to bind bFGF as a ligand selected from the group consisting of SEQ ID NOS: 7-69, 101-185, 281-319 and 330-444.

3. A purified and isolated non-naturally occurring nucleic acid ligand to bFGF wherein said ligand has substantially the same structure and substantially the same ability to bind bFGF as a ligand selected from the group consisting of SEQ ID NOS: 7-69, 101-185, 281-319 and 330-444.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Cipla
Cantor Fitzgerald
Fish and Richardson
Accenture
Federal Trade Commission
Farmers Insurance
Daiichi Sankyo
McKesson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot